Trial Search Results
Pharmacokinetics of Daunorubicin in Young Patients With Cancer
This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients with cancer. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about how patients respond to treatment with certain chemotherapy drugs.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Children's Oncology Group
Collaborator: National Cancer Institute (NCI)
Stanford Investigator(s):
Intervention(s):
- Other: pharmacological study
- Procedure: dual x-ray absorptimetry
Phase:
N/A
Eligibility
DISEASE CHARACTERISTICS:
- Diagnosis of any malignancy
- Must be receiving a chemotherapy regimen that includes daunorubicin hydrochloride
administered as an infusion of any duration for < 24 hours on either a 1- or a 2-day
schedule, including bolus and all short infusion schedules
PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- No significant uncontrolled systemic illness
- Large implanted prostheses allowed (should not undergo dual energy x-ray
absorptiometry scan)
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Ages Eligible for Study
N/A - 21 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting